Neurocrine

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C.

CEO

Kyle W. Gano

CEOKyle W. Gano

Employees

1,400

Employees1,400

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1992

Founded1992

Employees

1,400

Employees1,400

NBIX Key Statistics

Market cap

13.71B

Market cap13.71B

Price-Earnings ratio

36.28

Price-Earnings ratio36.28

Dividend yield

—

Dividend yield—

Average volume

1.22M

Average volume1.22M

High today

$137.01

High today$137.01

Low today

$134.12

Low today$134.12

Open price

$134.98

Open price$134.98

Volume

2.00M

Volume2.00M

52 Week high

$157.98

52 Week high$157.98

52 Week low

$110.95

52 Week low$110.95

NBIX News

TipRanks 1d

Neurocrine says Crenessity now available in U.S.

Neurocrine (NBIX) Biosciences announced Crenessity is now commercially available in the United States. Crenessity was recently approved by the U.S. FDA as an ad...

Investor's Business Daily 5d

Neurocrine Jumps After Snagging FDA Approval For A First-In-Decades Drug

Neurocrine Biosciences (NBIX) stock jumped Monday after the biotech company won Food and Drug Administration approval for the first new treatment for an adrenal...

Benzinga 5d

Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential

On Friday, the FDA approved Neurocrine Biosciences, Inc.NBIX Crenessity (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid r...

Analyst ratings

85%

of 27 ratings

Buy

85.2%

Hold

14.8%

Sell

More NBIX News

Investing.com 5d

Launch complexities temper expectations for Neurocrine Bio stock, says BMO Capital - Investing.com

...